Home Products Antibodies Primary antibodies Secondary antibodies Tag antibodies Loading control antibodies Premium polyclonal antibodies Recombinant rabbit mAbs Mouse mAbs Phosphorylated antibodies Methylation antibodies Acetylated antibodies Biochemicals Research Areas
Service & Support Custom Services Support Promotion About Us
Sign In Sign Up

RelB (Phospho-Ser573) Antibody  (Cat.#:AYP4366)

A
小A Scan to ask
Host: RabbitClonality: PolyclonalReactivity: Human,MouseWBIHCELISA
Cat.# AYP4366
Target / gene RELB
Host Rabbit
Clonality Polyclonal
Reactivity Human, Mouse
Application WB, IHC, ELISA

Cat.#:AYP4366

SizePrice
50 μL ¥1150.00 Add to cart
100 μL ¥2100.00 Add to cart
  • Information

  • Application guide

  • Related products

  • Immunogen

  • Target data

  • Resources

  • Protocols

  • FAQs

Reactivity Human,Mouse
Host Rabbit
Clonality Polyclonal
Isotype IgG
Application WBIHCELISA
Dilution WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
Predicted MW 62kDa
Observed MW
Format Liquid
Storage Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.75% BSA,50% glycerol,pH7.3.
Conjugate Unconjugated
Positive HeLa,HT-29,Jurkat
Subcellular Cytoplasm,Nucleus,centrosome,cytoskeleton,microtubule organizing center
Purification Affinity purification

Applications and conditions

Where to start

These starting conditions come from the recommended dilution, validation images, and general assay practice. Titrate for your sample and detection system.

WB Conditions for WB
Recommended dilution 1:500 - 1:2000
Suggested sample / positive control HeLa,HT-29,Jurkat
Key conditions Use a fresh lysate, incubate at the recommended dilution, and check the predicted and observed molecular weight
Expected result Expected signal or band near 62kDa
Controls Include a positive sample, a negative sample, and a secondary or isotype control
IHC Conditions for IHC
Recommended dilution 1:50 - 1:200
Suggested sample / positive control HeLa,HT-29,Jurkat
Key conditions For paraffin sections, optimize retrieval buffer pH, retrieval time, and primary incubation
Expected result Expected localization: Cytoplasm,Nucleus,centrosome,cytoskeleton,microtubule organizing center
Controls Include a positive sample, a negative sample, and a secondary or isotype control
ELISA Conditions for ELISA
Recommended dilution See the validation images or contact technical support
Suggested sample / positive control HeLa,HT-29,Jurkat
Key conditions Start at the recommended dilution and titrate for your sample and assay
Expected result Expected signal or band near 62kDa
Controls Include a positive sample, a negative sample, and a secondary or isotype control

Related products

More associated products >>

Immunogen

Immunogen Synthesized peptide derived from Human RelB (Phospho-Ser573).
Sequence
View sequence
GPGPQPHLVITEQPKQRGMRFRYECEGRSAGSILGESSTEASKTLPAIELRDCGGLREVEVTACLVWKDWPHRVHPHSLVGKDCTDGICRVRLRPHVSPRHSFNNLGIQCVRKKEIEAAIERKIQLGIDPYNAGSLKNHQEVDMNVVRICFQASYRDQQGQMRRMDPVLSEPVYDKKSTNTSELRICRINKESGPCTGGEELYLLCDKVQKEDISVVFSRASWEGRADFSQADVHRQIAIVFKTPPYEDLEIVEPVTVNVFLQRLTDGVCSEPLPFTYLPR

Target data

Background NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function.
Gene ID 5971
Gene name RELB
Swiss Q01201
Synonym RELB,I-REL,IREL,REL-B,RelB (Phospho-Ser573),RelB (Phospho-Ser573) Antibody
Functions NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed:26385063).
Research area

Resources

Validation data

Contact technical support for validation images and application examples.

References

No papers are linked yet. Contact technical support for application examples.

Ask for examples
Customer reviews

No reviews yet. After use, you can submit a review and experiment images.

Send feedback
Support

Support can help confirm the application, sample, dilution, controls, and assay conditions.

Support center
Need help with the application?

Send the catalog number, application, sample type, and assay. Support can confirm dilution, controls, and COA or lot documents.

FAQs

Listed applications: WB, IHC, ELISA. Use the validation images and recommended dilution as a starting point.
Send the catalog number and lot through the inquiry form. Support will help with the lot documents.
Use the recommended conditions as a starting concentration. Sample, fixation, and detection system may need a titration.

Protocols

Protocols
AYP4366